FITXR
FitXR is continuing to expand its popular virtual reality (VR) fitness offering with the UK, EU and Asia markets by launching on the popular PICO VR headsets. FitXR’s launch on PICO represents its commitment to make VR fitness accessible to all, irrespective of the user’s preference in hardware choice. As the mass market appeal in VR continues to grow, it will bring with it increased interest in hardware developers, innovation and consumer choice and in turn the desirability in multi-platform offerings like FitXR.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230323005314/en/
(Photo: Business Wire)
In January 2023, FitXR launched two new studio offerings: Sculpt and Combat, to add to its already robust suite of offerings that include High Intensity Interval Training (HIIT), Dance and Box workout options. The launch of Sculpt (workouts inspired by barre, pilates, and isometric strength training) and Combat (workouts inspired by karate, muay thai and taekwondo) support FitXR’s continued mission to provide the widest variety of workout experiences available in the metaverse today.
FitXR is now reaching new audiences by bringing its at-home virtual fitness experience to PICO headsets. Starting today, any consumer who downloads FitXR onto their PICO 4 or PICO Neo Link 3 headset will get 30 days free membership; an offer running until the 30th of April.
“Launching on PICO is a pivotal moment for FitXR,” said Sam Cole, CEO and Co-founder of FitXR. “We already offer the most diverse and unique fitness experience, and by expanding to the new PICO headset, we’re furthering our aim to provide this to every person, in every household, in every geography, and on any hardware device. It also reinforces our position as the leading global VR Fitness app with members around the world.”
“For PICO, launching FitXR as a subscription app on our platform underlines our commitment to bring the widest variety of high quality and customizable fitness experiences to our customers,” said Peter Li, Head of Gaming Partnerships at PICO.
FitXR’s launch on PICO is also indicative of the heightened appetite for combining technology and gaming to provide the optimal fitness experience. On FitXR, users can access different fitness studios whilst customising these experiences to meet their goals. Every time members enter the app, they can choose exactly how they want to work out; by studio type, music genre, intensity level, and/or time duration and then choose from one of many fully immersive 3D workout environments. Members can Dance or Box on a downtown city building rooftop, take Sculpt classes on the beachfront seaside or fight and defend in an outdoor martial arts-inspired Combat arena - all while punching flying fireballs, earning points and extending their winning streak.
“We never forget to bring the fun. The fun matters just as much as the results,” said Lisa Raggiri, Chief Marketing Officer at FitXR. “Whilst all of our classes are choreographed by certified fitness instructors to ensure results, we are strong believers in leveraging the unique immersive nature of VR to provide a fun escape. We know that by jumping into a fully immersive workout, our members have greater enjoyment, improve their consistency and see real results.”
In case variety, customization, gamification and numerous 3D environments wasn’t enough, FitXR is launching its first Box Training Program created in partnership with Olympic Boxing Champion Nicola Adams.
Says Nicola: “I am so excited to be able to finally share that I’ve been working closely alongside FitXR on this new boxing starter program, Box Like a Pro. We’ve broken it down and will delve into the principles of boxing – whether you’re looking to work on the perfect stance or refining your uppercut, this program is one for all. Regardless of your level, this program provides both beginners and intermediate boxers with the foundations and technical skills to build on and succeed. Having begun boxing at a young age, it’s been vital in helping build up my confidence and I hope users step away from this program feeling stronger and more energized, both mentally and physically. My hope is that I can inspire people to get more active, build and maintain a healthy lifestyle and show that fitness can be fun! I love spending weekends gaming, so I’ve enjoyed being able to blend it into fitness with FitXR. It’s been inspiring to partner with FitXR who have made transformative strides in elevating fitness for the better and making it more inclusive for all.”
About FitXR:
FitXR merges immersive VR with total body workouts designed by top fitness experts. Dedicated to making fitness more fun and accessible for everyone, FitXR offers classes within five distinct workout studios - Box, Dance, HIIT, Sculpt and Combat. FitXR provides a truly engaging, multiplayer experience along with constantly refreshed classes, environments and music. FitXR is available on Meta Quest 2.
About PICO:
Founded in March 2015, PICO is a leading VR company with independent innovation and R&D capabilities, focusing on VR all-in-one technology. Embracing a mission to bridge connections, enrich life, and release infinity, PICO is committed to building an integrated XR platform that inspires the community and empowers developers, creators, and businesses. To learn more, visit picoxr.com or business.picoxr.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230323005314/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
